ViiV’s Dolutegravir/Lamivudine FDA Approved for HIV-Positive Adolescents
The U.S. Food and Drug Administration (FDA) has approved the use of Dovato for treating HIV-1 infection in adolescents...
Jon Napitupulu
Boundless Bio Unveils Preclinical and Clinical Data on ecdna-Directed BBI-355
Boundless Bio presents findings from preclinical and clinical studies of BBI-355, a novel inhibitor of checkpoint kinase 1 (CHK1),...
Alterome Uncovers Pre-Clinical Data for Lead AKT1 E17K Inhibitor Program Development
Alterome Therapeutics has developed ALTA-2618, a potent and selective covalent inhibitor targeting the AKT1 E17K mutation found in various...
AltPep Study in Nature Journal Affirms Potential of Blood Test for Alzheimer’s Detection
AltPep Corporation’s SOBA-AD blood test has demonstrated promising accuracy in detecting Alzheimer’s diseaseAlzheimer’s disease (AD) in two independent studies....
Bristol Myers Squibb & 2Seventy Abecma Expands Approval for Multiple Myeloma Treatment
Abecma, a personalized CAR T cell therapy, has received expanded approval from the FDA for the treatment of adult...
Alnylam Unveils Positive KARDIA-2 Phase 2 Results for Zilebesiran in Hypertensive Patients
The KARDIA-2 Phase 2 study evaluated the efficacy and safety of zilebesiran, an RNAi therapeutic targeting hypertension, when added...
Merck Launches Phase 3 Trial with Combo of MK-1084 & KeytrudaⓇ for NSCLC Treatment
Merck has initiated a Phase 3 clinical trial (NCT06345729) to evaluate MK-1084, an oral KRAS G12C inhibitor, in combination...
FDA Grants 510(k) Clearance to Angiodynamics’ AlphaVac F1885 System for PE Treatment
AngioDynamics has received FDA clearance for the AlphaVac F1885 System to treat pulmonary embolism (PE), a life-threatening condition. PE...
Allurion Bridges Digital Gap, Introduces Virtual Care Suite in US
Allurion Technologies has launched its Virtual Care Suite (VCS) in the United States. It provides a comprehensive weight loss...
EC Approves Bristol Myers’ Reblozyl as First-Line Treatment for LR-MDS Anemia
The European Commission (EC) has expanded approval of Reblozyl (luspatercept), a first-in-class treatment for patients with disease-related anemia, for...